iXensor Co., Ltd.

iXensor Co., Ltd. specializes in point-of-care testing (POCT) systems and diagnostic test kits. Their portfolio includes analyzers and test strips for measuring hemoglobin A1c (HbA1c) and lipid levels, as well as fertility and ovulation testing devices like the Eveline Ovulation Test and PHRONESIA Smart Ovulation Test. These products are designed for quick, accessible diagnostic results outside traditional clinical settings.

iXensor Co., Ltd. is based in Taiwan. Since their devices are listed in both the EU’s eudamed registry and the FDA’s 510(k) database, they operate in markets with distinct regulatory requirements. The EU categorizes their Class II IVD devices under IVD General and self-testing classifications, while the FDA’s 510(k) pathway applies to their submissions in the US, reflecting compliance with regional regulatory frameworks.

iXensor Co., Ltd.’s devices are listed in eudamed (the EU’s IVD registry) and the FDA’s 510(k) database (for US clearance). Inclusion in these registries demonstrates compliance with EU and US regulatory requirements for IVD devices. eudamed ensures traceability under EU MDR, while 510(k) submissions indicate FDA-premarket notification approval for devices marketed in the US, both critical for market access and transparency.

iXensor Co., Ltd.’s devices are classified as Class II in vitro diagnostic (IVD) devices, including those intended for self-testing. This classification is determined by factors like the device’s risk level, intended use, and potential health impact. Class II devices require stricter regulatory oversight than Class I but are not as high-risk as Class III, aligning with their role in POCT and fertility testing where accuracy and safety are critical but not life-threatening.